AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cimetidine (H2 antagonist) and chlorpheniramine (H1 antagonist)
Number of subjects: 12
Study 393182 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine (H1 antagonist)
Number of subjects: 12
Study 393182 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (H2 antagonist)
Number of subjects: 12
Study 393182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6353233 — intervention group
Group type: EXPERIMENTAL
Intervention: semustine (methyl‐CCNU)
Number of subjects: 3633
Study 6353233 — intervention group
Group type: COMPARATOR
Intervention: other therapies
Number of subjects: 3633
Study 30636547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 1294
Study 30636547 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet)
Number of subjects: 1294
Study 30215466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (4 mg, 5 min)
Number of subjects: 90
Study 30215466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine (25 mg, 25 min)
Number of subjects: 90
Study 30215466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer (500 ml, 20 min)
Number of subjects: 90
Study 26579834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1160
Study 26579834 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1160
Study 26579834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 26579834 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 1160
Study 26579834 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1160
Study 24126180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear stem cells
Number of subjects: 18
Study 24126180 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 18
Study 22408779 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 6 months
Number of subjects: 0
Study 22408779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22408779 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate discontinued after 6 months
Number of subjects: 0
Study 22408779 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate administered after osseointegration for 6 months
Number of subjects: 0
Study 19409337 — intervention group
Group type: EXPERIMENTAL
Intervention: FR-2 appliance of Fränkel
Number of subjects: 30
Study 19409337 — intervention group
Group type: COMPARATOR
Intervention: Untreated Class II control group
Number of subjects: 30
Study 16934332 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 6
Study 16934332 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 15845179 — intervention group
Group type: COMPARATOR
Intervention: Continuous thoracic radiation therapy (50 Gy delivered in 2.0-Gy fractions over 5 weeks)
Number of subjects: 110
Study 15845179 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdigitating split-course thoracic radiation therapy (50 Gy delivered in 2.5-Gy fractions over 8 weeks)
Number of subjects: 110
Study 12120883 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol glycinate acetylcysteinate (TGA)
Number of subjects: 0
Study 12120883 — intervention group
Group type: COMPARATOR
Intervention: Thiamphenicol glycinate (TG)
Number of subjects: 0
Study 10630349 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal treatment prescribed by traditional healers
Number of subjects: 306
Study 10630349 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment or acyclovir (Control)
Number of subjects: 306
Study 7790606 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 38
Study 7790606 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (5 mbar)
Number of subjects: 38
Study 7790606 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV (7 mbar, PEEP 5 mbar)
Number of subjects: 38
Study 2088624 — intervention group
Group type: EXPERIMENTAL
Intervention: Plax prebrushing rinse
Number of subjects: 103
Study 2088624 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 103
Study 388513 — intervention group
Group type: EXPERIMENTAL
Intervention: Rayvist (Ioglicinate)
Number of subjects: 100
Study 388513 — intervention group
Group type: COMPARATOR
Intervention: Telebrix (Ioxithalamate)
Number of subjects: 100
Study 31050715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg daily)
Number of subjects: 42
Study 31050715 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg potassium daily)
Number of subjects: 42
Study 31050715 — intervention group
Group type: COMPARATOR
Intervention: Empty control (no pill)
Number of subjects: 42
Study 29220533 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Androgen Index (FAI)
Number of subjects: 1422
Study 29220533 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular Menses (IM)
Number of subjects: 1422
Study 29220533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FAI and IM
Number of subjects: 1422
Study 26507858 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with budesonide induction and azathioprine maintenance
Number of subjects: 36
Study 26507858 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment with open ileocaecal resection
Number of subjects: 36
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 200
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 200
Study 24299928 — intervention group
Group type: COMPARATOR
Intervention: saline (Early-control)
Number of subjects: 200
Study 24299928 — intervention group
Group type: COMPARATOR
Intervention: saline (Late-control)
Number of subjects: 200
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (Early)
Number of subjects: 200
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Early)
Number of subjects: 200
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (Late)
Number of subjects: 200
Study 24299928 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Late)
Number of subjects: 200
Study 22271072 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin
Number of subjects: 100
Study 22271072 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 100
Study 19021129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing knowledge of chemotherapy-associated cognitive problems
Number of subjects: 261
Study 19021129 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with an introduction letter mentioning cognitive complaints
Number of subjects: 261
Study 19021129 — intervention group
Group type: COMPARATOR
Intervention: Neutral letter (control)
Number of subjects: 261
Study 17326973 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP ventilation combined with lung recruitment maneuvers (LRM)
Number of subjects: 28
Study 17326973 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume A/C ventilation (control group)
Number of subjects: 28
Study 16355649 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluoride (F) mucosa adhesive paste (Orabase)
Number of subjects: 6
Study 16355649 — intervention group
Group type: COMPARATOR
Intervention: Placebo product without fluoride
Number of subjects: 6
Study 12455727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557
Study 12455727 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 557
Study 9973871 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Acceptable Weight of Lift (MAWL)
Number of subjects: 0
Study 9973871 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Safe Weight of Lift (MSWL)
Number of subjects: 0
Study 9973871 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic Magnitude Estimation (LME) method
Number of subjects: 0
Study 9973871 — intervention group
Group type: EXPERIMENTAL
Intervention: Load indifference concept
Number of subjects: 0
Study 7852666 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (once daily slow-release, mean serum concentration 16 +/- 5 micrograms/ml)
Number of subjects: 16
Study 7852666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (2 mg administered by MDI four times daily)
Number of subjects: 16
Study 7852666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7852666 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (once daily slow-release)
Number of subjects: 16
Study 2187372 — intervention group
Group type: EXPERIMENTAL
Intervention: Piritramide (n = 17)
Number of subjects: 54
Study 2187372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (n = 20)
Number of subjects: 54
Study 2187372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 54
Study 498698 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol treatment (200 to 400 mg twice daily)
Number of subjects: 6
Study 31815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative science messages with hero characters
Number of subjects: 90
Study 31815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative science messages with victim-to-hero characters
Number of subjects: 90
Study 31815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative science messages with victim characters
Number of subjects: 90
Study 31815957 — intervention group
Group type: COMPARATOR
Intervention: Conventional science messages using probability language
Number of subjects: 90
Study 31815957 — intervention group
Group type: COMPARATOR
Intervention: Conventional science messages using certainty language
Number of subjects: 90
Study 31815957 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative science messages (overall)
Number of subjects: 90
Study 29100199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management model (12-week intervention)
Number of subjects: 134
Study 29100199 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 134
Study 26129898 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at Tongli (HT 5) and Xuanzhong (GB 39) acupoints (ACU)
Number of subjects: 15
Study 26129898 — intervention group
Group type: COMPARATOR
Intervention: Electro-acupuncture at bilateral non-acupoints (NAP)
Number of subjects: 15
Study 24794093 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret 100mg
Number of subjects: 171
Study 24794093 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret 200mg
Number of subjects: 171
Study 24794093 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret 300mg
Number of subjects: 171
Study 24794093 — intervention group
Group type: EXPERIMENTAL
Intervention: ronacaleret 400mg
Number of subjects: 171
Study 24794093 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate 70mg
Number of subjects: 171
Study 24794093 — intervention group
Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 171
Study 23117318 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-label closure
Number of subjects: 133
Study 23117318 — intervention group
Group type: COMPARATOR
Intervention: CLOSURE I
Number of subjects: 133
Study 19527386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral lycopene daily
Number of subjects: 159
Study 19527386 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 159
Study 17654408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 24
Study 17654408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (CBT)
Number of subjects: 24
Study 17654408 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacological and psychological treatment
Number of subjects: 24
Study 17654408 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (pharmacological and psychological)
Number of subjects: 24
Study 17654408 — intervention group
Group type: COMPARATOR
Intervention: Generalized anxiety disorder treatments
Number of subjects: 24
Study 15204794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafine particles at 50 microg/m(3)
Number of subjects: 16
Study 15204794 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study 11430599 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mental health nursing contact
Number of subjects: 274
Study 11430599 — intervention group
Group type: COMPARATOR
Intervention: No community mental health nursing contact
Number of subjects: 274
Study 9488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure ventriculoperitoneal shunt (LPV; 40 +/- 10 mm H2O)
Number of subjects: 96
Study 9488303 — intervention group
Group type: COMPARATOR
Intervention: Medium-pressure ventriculoperitoneal shunt (MPV; 100 +/- 10 mm H2O)
Number of subjects: 96
Study 7836023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0
Study 7836023 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 7836023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3126525 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 12
Study 3126525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31939839 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated management of anesthetic depth, cardiac blood flow, and protective lung ventilation using three independent controllers
Number of subjects: 90
Study 31939839 — intervention group
Group type: COMPARATOR
Intervention: Manual control of anesthesia management
Number of subjects: 90
Study 31939839 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated management
Number of subjects: 90
Study 31939839 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 90
Study 29371105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) in combination with one to two NRTIs
Number of subjects: 244
Study 29371105 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitors (PI/r) in combination with one to two NRTIs
Number of subjects: 244
Study 27981552 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 86
Study 27981552 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional radiotherapy
Number of subjects: 86
Study 25071075 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-unsaturated/low-saturated fat diet (LC)
Number of subjects: 115
Study 25071075 — intervention group
Group type: COMPARATOR
Intervention: High-unrefined carbohydrate, low-fat diet (HC)
Number of subjects: 115
Study 22227833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness induction task
Number of subjects: 0
Study 22227833 — intervention group
Group type: COMPARATOR
Intervention: Unfocused-attention induction task (Control)
Number of subjects: 0
Study 20975464 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated lidocaine/tetracaine patch (active patch)
Number of subjects: 25
Study 20975464 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 25
Study 17942819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (20 IU BID)
Number of subjects: 25
Study 17942819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 16313838 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine (H2 strain)
Number of subjects: 220
Study 16313838 — intervention group
Group type: COMPARATOR
Intervention: Vaccine coverage
Number of subjects: 220
Study 12202710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol with iodine concentration of 370 mg/mL (Group B)
Number of subjects: 201
Study 12202710 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol with iodine concentration of 300 mg/mL (Group A)
Number of subjects: 201
Study 10493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) patients (n = 13)
Number of subjects: 25
Study 10493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA) patients (n = 6)
Number of subjects: 25
Study 10493664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid factor positive RA patients (n = 8)
Number of subjects: 25
Study 8670596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminohexane bisphosphonate 400 mg (AHBP)
Number of subjects: 25
Study 8670596 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol valerate 2 mg and dydrogesterone 5 mg (E/D)
Number of subjects: 25
Study 8375265 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurothesiometer
Number of subjects: 85
Study 8375265 — intervention group
Group type: COMPARATOR
Intervention: Biothesiometer
Number of subjects: 85
Study 8375265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 85
Study 2872795 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (10 mg)
Number of subjects: 13
Study 2872795 — intervention group
Group type: EXPERIMENTAL
Intervention: nadolol (80 mg)
Number of subjects: 13
Study 2872795 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (400 mg)
Number of subjects: 13
Study 2872795 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 13
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: KSHV seropositivity in KS positive patients
Number of subjects: 150
Study 30176543 — intervention group
Group type: COMPARATOR
Intervention: KSHV seropositivity in KS negative patients
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggregate variation in EPHA2 coding region
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in Pkinase-Tyr domain
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in SAM domain
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: c.2254 T>C variant in Pkinase-Tyr
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: c.2990 G>T variant in SAM
Number of subjects: 150
Study 30176543 — intervention group
Group type: EXPERIMENTAL
Intervention: c.2727 C>T variant in Pkinase-Tyr
Number of subjects: 150
Study 27081036 — intervention group
Group type: EXPERIMENTAL
Intervention: CEpOP +/− rituximab (R) with epirubicin (70 mg/m2/dose)
Number of subjects: 398
Study 27081036 — intervention group
Group type: COMPARATOR
Intervention: CHOP +/− rituximab (R) with doxorubicin (50 mg/m2/dose)
Number of subjects: 398
Study 25352653 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine titrated to a fasting glucose level of ≤5.3 mmol/L (≤95 mg/dL)
Number of subjects: 12537
Study 25352653 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 12537
Study 24321804 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg once daily
Number of subjects: 523
Study 24321804 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol-fluticasone (SFC) 50/500 μg twice daily
Number of subjects: 523
Study 21402550 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) concurrent with tuberculosis treatment for 6 months
Number of subjects: 74
Study 21402550 — intervention group
Group type: COMPARATOR
Intervention: Tuberculosis treatment alone
Number of subjects: 74
Study 19892052 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 328
Study 19892052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 328
Study 19892052 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 328
Study 19892052 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 328
Study 17143364 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia using 0.2% Ropivacaine (group 1)
Number of subjects: 80
Study 17143364 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 80
Study 12913647 — intervention group
Group type: EXPERIMENTAL
Intervention: Two screws applied laterally and parallel
Number of subjects: 64
Study 12913647 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density measurement
Number of subjects: 64
Study 12913647 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5‐mm cannulated screws applied parallel from the lateral direction
Number of subjects: 64
Study 12913647 — intervention group
Group type: EXPERIMENTAL
Intervention: Range‐of‐motion exercises producing bending stress
Number of subjects: 64
Study 10832512 — intervention group
Group type: EXPERIMENTAL
Intervention: Real age of acquisition norms derived from children's naming data
Number of subjects: 0
Study 10832512 — intervention group
Group type: EXPERIMENTAL
Intervention: Word frequency and orthographic neighbourhood size
Number of subjects: 0
Study 10832512 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageability
Number of subjects: 0
Study 10832512 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of the word's initial phoneme
Number of subjects: 0
Study 8522796 — intervention group
Group type: EXPERIMENTAL
Intervention: Training courses educating workers on proper lifting techniques
Number of subjects: 40
Study 2039205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg twice a day)
Number of subjects: 33
Study 2039205 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotics (cefazolin, 1.0 g intravenously every 8 h, or ceftazidime, 2.0 g intravenously every 12 h)
Number of subjects: 33
Study 6753642 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental, 15 mg/kg
Number of subjects: 204
Study 6753642 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 204
Study 31257453 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 50 mg plus MTX
Number of subjects: 0
Study 31257453 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 25 mg plus MTX
Number of subjects: 0